West Pharmaceutical Services, Inc. (NYSE:WST – Get Free Report) gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $286.44, but opened at $327.50. West Pharmaceutical Services shares last traded at $350.50, with a volume of 288,188 shares traded.
The medical instruments supplier reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.34. The company had revenue of $746.90 million for the quarter, compared to analysts’ expectations of $709.62 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.16 earnings per share.
West Pharmaceutical Services Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 20th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Wednesday, November 13th. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.20. West Pharmaceutical Services’s payout ratio is currently 11.08%.
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. LGT Group Foundation acquired a new stake in West Pharmaceutical Services during the second quarter valued at approximately $68,854,000. Liontrust Investment Partners LLP acquired a new stake in West Pharmaceutical Services during the second quarter valued at approximately $64,196,000. Findlay Park Partners LLP raised its stake in West Pharmaceutical Services by 30.6% during the first quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock valued at $236,281,000 after buying an additional 139,800 shares in the last quarter. Iron Triangle Partners LP acquired a new stake in West Pharmaceutical Services during the first quarter valued at approximately $47,381,000. Finally, ProShare Advisors LLC raised its stake in West Pharmaceutical Services by 13.9% during the first quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock valued at $198,117,000 after buying an additional 61,247 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.
West Pharmaceutical Services Price Performance
The company has a 50 day simple moving average of $300.51 and a 200-day simple moving average of $322.27. The stock has a market cap of $22.43 billion, a price-to-earnings ratio of 40.62, a PEG ratio of 10.21 and a beta of 1.01. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Recommended Stories
- Five stocks we like better than West Pharmaceutical Services
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Texas Roadhouse Stock Steering for New Highs This Year
- Comparing and Trading High PE Ratio Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Warren Buffett Stocks to Buy Now
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.